AT 10:55:33 ON 16 JAN 2004)

FILE 'REGISTRY' ENTERED AT 10:55:47 ON 16 JAN 2004

```
L1             0 S GINKGO BILOBA/CN
L2           189 S GINKGO BILOBA
L3             0 S GINGO BILOBA
L4             1 S PVP/CN
L5             2 S MANNITOL/CN
L6           194 S GINKGO
```

FILE 'USPATFULL, CAPLUS, KOSMET, EMBASE' ENTERED AT 11:13:11 ON 16 JAN 2004

```
L7           156 S L6
L8         92283 S L5 OR MANNITOL
L9         82276 S L4 OR PVP OR POLYVINYLPYRROLIDONE
L10            0 S L7 AND L8 AND L9
L11            0 S L7 AND L8
L12            1 S L7 AND L9
L13         5267 S GINKGO BILOBA
L14       423686 S HIS
L15           40 S L13 AND L8 AND L9
L16           40 DUPLICATE REMOVE L15 (0 DUPLICATES REMOVED)
```

FILE 'STNGUIDE' ENTERED AT 11:15:47 ON 16 JAN 2004

FILE 'USPATFULL, CAPLUS, KOSMET, EMBASE' ENTERED AT 11:31:33 ON 16 JAN 2004

```
L17           33 S L16 AND COAT####
```

=>

. . . within the first 20 min of the test; and ii) a second NSAID-containing fraction of multiple-units in the form of **coated** delayed release multiple units for extended release of the NSAID substance, said units **coated** with a **coating** substantially water-insoluble, but water-diffusible and substantially pH-independent, wherein said second NSAID-containing fraction of multiple-units releases from about 6% to 30%. . .

6. The composition according to claim 1, wherein the first NSAID-containing fraction is present in the form of **coated** units and the NSAID substance contained in the first fraction has a pK.sub.a value of at least 5.0.

7. The composition according to claim 1, wherein the first NSAID-containing fraction is present in the form of **coated** units and the NSAID substance has a solubility in 0.1 N hydrochloric acid at room temperature of at least about. . .

. . . obtain a therapeutically and/or prophylactically active plasma concentration within a relatively short period of time, and a second fraction of **coated** modified release multiple-units for extended release in vivo of an NSAID substance to maintain a therapeutically and/or prophylactically active plasma. . .

33. The composition according to claim 1, wherein the multiple-units of the second fraction are **coated** cross-sectionally substantially homogeneous pellets.

35. The composition according to claim 1, wherein the first fraction is **coated** units and the **coating** is a substantially water-insoluble, but water-diffusible and substantially pH-independent **coating**.

44. A process for the preparation of a unit dosage form of an oral pharmaceutical modified release composition comprising the. . . of the NSAID substance is released within the first 20 min of the test; ii)

providing a second fraction of **coated** extended release multiple-units for extended release in vivo of an NSAID substance, wherein said **coated**-units comprise a **coating** substantially water-insoluble, but water-diffusible and substantially pH-independent; iii) combining and formulating the first and the second fractions with respect to. . .

. . . w/w of the NSAID substance is released within the first 20 min of the

test; and a second fraction of **coated** modified release multiple-units for extended release in vivo of an NSAID substance to maintain a therapeutically and/or prophylactically active plasma concentration, wherein each of the multiple-units is **coated** with a **coating** substantially water-insoluble, but water-diffusible, and substantially pH-independent, wherein said second NSAID-containing fraction of multiple-units releases from about 6% to 30%. . .

the intended use. Additions of dextrans, modified starches, sugars and, in particular, **mannitol**, allow, for example, pellets to be prepared according to the invention which dissolve in cold water spontaneously and completely.

DETD 50 g of **mannitol**

DETD The collagen hydrolysate, the wheat protein hydrolysate and the **mannitol** are dissolved in the cold Aloe vera juice, which has been processed as shown in Example 6, and pellets are. . .

CLM What is claimed is:

. . . arabic, pectins, tragacanth, xanthan, natural and modified starches, dextrans, dextrins, maltodextrin, chitosan, alginates, cellulose derivatives, dextran, sugars, glycine, lactose, sorbitol, **mannitol** or **polyvinylpyrrolidone**.

. . . gum arabic, pectins, tragacanth, xanthan, natural and modified starches, dextrans, dextrins, maltodextrin, chitosan, alginates, cellulose derivatives, dextran, sugars, glycine, lactose, **mannitol** or **polyvinylpyrrolidone** is added to the dispersion of skeleton builder and plant extract.

IT 50-70-4, Sorbitol, biological studies 56-40-6, Glycine, biological studies 63-42-3, Lactose **69-65-8**, D-Mannitol **9003-39-8**, PVP 9004-54-0, Dextran, biological studies
(pellets contg. dihydropyridine deriv. drug and)